Posted on July 27, 2026August 28, 2026 by — Leave a comment

GLOW Blend 50mg Dosage Protocol

Preparation & Measurement Guide

GLOW Blend 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a GLOW Blend 50mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
5mg BPC-157 + 35mg GHK-CU + 10mg TB-500

Preparation
2mL bacteriostatic water

Concentration
25mg/mL after preparation

Documented Convention
2.5mg total once daily

1. Preparation and Measurement

GLOW Blend 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL

1 U-100 unit = 0.01mL = 250mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily for four weeks.

Period	Documented amount	Measurement
Weeks 1-4	2.5mg total once daily	0.1mL / 10 units

Vial estimate: One 50mg vial contains approximately 20 documented-size administrations at 2.5mg.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
At 10 units: 250mcg BPC-157, 1.75mg GHK-CU, and 500mcg TB-500.
Record the amount, date, and preparation used.

3. Supplies Needed

GLOW Blend 50mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

GLOW combines BPC-157, GHK-CU, and TB-500 in a fixed ratio. The exact three-component blend has not been evaluated in controlled human trials.

Research on individual components cannot establish the combined material’s safety, efficacy, interactions, or optimal schedule. The table records a circulated total-mass convention only.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

BPC-157 + TB-500 5mg+5mg Dosage Protocol

Preparation & Measurement Guide

BPC-157 + TB-500 5mg+5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a BPC-157 + TB-500 5mg+5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
5mg BPC-157 + 5mg TB-500

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
500mcg-1mg total once daily

1. Preparation and Measurement

BPC-157 + TB-500 5mg+5mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period	Documented amount	Measurement
Weeks 1-2	250mcg BPC-157 + 250mcg TB-500 once daily	0.1mL / 10 units
Weeks 3-4	375mcg BPC-157 + 375mcg TB-500 once daily	0.15mL / 15 units
Weeks 5-8	500mcg BPC-157 + 500mcg TB-500 once daily	0.2mL / 20 units

Vial estimate: One 10mg vial contains approximately 20 administrations at the first listed amount or 10 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
The vial contains 5mg BPC-157 + 5mg TB-500; all measurements preserve that fixed component ratio.
Record the amount, date, and preparation used.

3. Supplies Needed

BPC-157 + TB-500 5mg+5mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

BPC-157 and thymosin-related peptides have separate preclinical research histories, but the exact combined vial has not been validated in controlled human trials.

The blend is not an approved therapeutic drug. Findings for either component alone cannot establish the safety, efficacy, or interaction profile of the combination.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

CJC-1295 + Ipamorelin 5mg+5mg Dosage Protocol

Preparation & Measurement Guide

CJC-1295 + Ipamorelin 5mg+5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a CJC-1295 + Ipamorelin 5mg+5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
5mg CJC-1295 + 5mg Ipamorelin

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
100-200mcg of each once daily

1. Preparation and Measurement

CJC-1295 + Ipamorelin 5mg+5mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period	Documented amount	Measurement
Weeks 1-2	100mcg CJC-1295 + 100mcg Ipamorelin once daily	0.04mL / 4 units
Weeks 3-4	150mcg CJC-1295 + 150mcg Ipamorelin once daily	0.06mL / 6 units
Weeks 5-8	200mcg CJC-1295 + 200mcg Ipamorelin once daily	0.08mL / 8 units

Vial estimate: One 10mg vial contains approximately 50 administrations at the first listed amount or 25 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Some entries are very small measurements; account for the accuracy of the measuring device.
The vial contains 5mg CJC-1295 + 5mg Ipamorelin; all measurements preserve that fixed component ratio.
Record the amount, date, and preparation used.

3. Supplies Needed

CJC-1295 + Ipamorelin 5mg+5mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

CJC-1295 and ipamorelin have each been studied for effects on growth-hormone signalling, but published studies do not validate this exact combined vial or the staged schedule shown here.

The blend is not an approved therapeutic drug. Component evidence cannot establish the safety or efficacy of the combined research material.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Epitalon 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Epitalon 10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
Epitalon 10mg

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
5mg daily for 10-20 days

1. Preparation and Measurement

Epitalon 10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily for a defined cycle.

Period	Documented amount	Measurement
Days 1-10	5mg once daily	1mL / 100 units
Days 11-20	5mg once daily, when a 20-day convention is documented	1mL / 100 units

Vial estimate: One 10mg vial contains approximately 2 documented-size administrations at 5mg.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Epitalon 10mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Epitalon has been examined mainly in cell and animal models involving telomerase, oxidative stress, and aging-related pathways. Human evidence is limited and does not establish a standard protocol.

Epitalon is not an approved therapeutic drug. The 10-20 day table records a commonly circulated convention rather than a validated clinical schedule.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

Epitalon 50mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a Epitalon 50mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
Epitalon 50mg

Preparation
2mL bacteriostatic water

Concentration
25mg/mL after preparation

Documented Convention
5mg daily for 10-20 days

1. Preparation and Measurement

Epitalon 50mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 25mg/mL. On a U-100 syringe, each unit contains 250mcg.

50mg / 2mL = 25mg/mL

1 U-100 unit = 0.01mL = 250mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily for a defined cycle.

Period	Documented amount	Measurement
Days 1-10	5mg once daily	0.2mL / 20 units
Days 11-20	5mg once daily, when a 20-day convention is documented	0.2mL / 20 units

Vial estimate: One 50mg vial contains approximately 10 documented-size administrations at 5mg.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Record the amount, date, and preparation used.

3. Supplies Needed

Epitalon 50mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

Epitalon has been examined mainly in cell and animal models involving telomerase, oxidative stress, and aging-related pathways. Human evidence is limited and does not establish a standard protocol.

Epitalon is not an approved therapeutic drug. The 10-20 day table records a commonly circulated convention rather than a validated clinical schedule.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

GHK-CU 100mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a GHK-CU 100mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
GHK-CU 100mg

Preparation
2mL bacteriostatic water

Concentration
50mg/mL after preparation

Documented Convention
1-2mg, five days weekly

1. Preparation and Measurement

GHK-CU 100mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 50mg/mL. On a U-100 syringe, each unit contains 500mcg.

100mg / 2mL = 50mg/mL

1 U-100 unit = 0.01mL = 500mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated vial protocols. Frequency: five days per week.

Period	Documented amount	Measurement
Weeks 1-2	1mg once daily, five days per week	0.02mL / 2 units
Weeks 3-4	1.5mg once daily, five days per week	0.03mL / 3 units
Weeks 5-8	2mg once daily, five days per week	0.04mL / 4 units

Vial estimate: One 100mg vial contains approximately 100 administrations at the first listed amount or 50 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
Some entries are very small measurements; account for the accuracy of the measuring device.
Record the amount, date, and preparation used.

3. Supplies Needed

GHK-CU 100mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

GHK-Cu has been studied in wound, tissue-remodelling, gene-expression, and skin research. Much of the literature uses topical, cell, or animal models rather than injectable human protocols.

GHK-Cu is not approved as an injectable therapeutic drug. The table records a circulated vial convention only.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

BPC-157 + TB-500 10mg+10mg Dosage Protocol

Preparation & Measurement Guide

BPC-157 + TB-500 10mg+10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a BPC-157 + TB-500 10mg+10mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
10mg BPC-157 + 10mg TB-500

Preparation
2mL bacteriostatic water

Concentration
10mg/mL after preparation

Documented Convention
500mcg-1mg total once daily

1. Preparation and Measurement

BPC-157 + TB-500 10mg+10mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 10mg/mL. On a U-100 syringe, each unit contains 100mcg.

20mg / 2mL = 10mg/mL

1 U-100 unit = 0.01mL = 100mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated protocols. Frequency: once daily.

Period	Documented amount	Measurement
Weeks 1-2	250mcg BPC-157 + 250mcg TB-500 once daily	0.05mL / 5 units
Weeks 3-4	375mcg BPC-157 + 375mcg TB-500 once daily	0.075mL / 7.5 units
Weeks 5-8	500mcg BPC-157 + 500mcg TB-500 once daily	0.1mL / 10 units

Vial estimate: One 20mg vial contains approximately 40 administrations at the first listed amount or 20 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 2mL.
The vial contains 10mg BPC-157 + 10mg TB-500; all measurements preserve that fixed component ratio.
Record the amount, date, and preparation used.

3. Supplies Needed

BPC-157 + TB-500 10mg+10mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

BPC-157 and thymosin-related peptides have separate preclinical research histories, but the exact combined vial has not been validated in controlled human trials.

The blend is not an approved therapeutic drug. Findings for either component alone cannot establish the safety, efficacy, or interaction profile of the combination.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

BPC-157 10mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a BPC-157 10mg vial.

Research use only
Educational summary of a commonly published convention. Not approved for human use.

Vial Size
10mg BPC-157

Preparation
2mL bacteriostatic water

Concentration
5mg/mL after preparation

Published Convention
200-600mcg once daily

1. Preparation and Measurement

10mg Vial With 2mL of Diluent

Add 2mL of bacteriostatic water to the 10mg vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

10mg / 2mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 2mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous. Frequency: once daily.

Period	Documented daily amount	Measurement
Weeks 1-2	200mcg once daily	0.04mL / 4 units
Weeks 3-4	400mcg once daily	0.08mL / 8 units
Weeks 5-8+	600mcg once daily	0.12mL / 12 units

One 10mg vial lasts approximately: 50 days at 200mcg, 25 days at 400mcg, or 16 days at 600mcg.

Practical Notes

The table applies only to a 10mg vial prepared with exactly 2mL.
Four units is a small measurement; account for the accuracy of the measuring device.
Record the amount, date, and preparation used.

3. Supplies Needed

BPC-157 10mg vial.
2mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

BPC-157 has been examined mainly in animal and cell studies involving tendon response, fibroblasts, angiogenic signaling, wound models, and gastrointestinal injury. These findings do not establish human efficacy or a clinically validated dose.

BPC-157 is not an approved therapeutic drug. FDA materials note limited human safety information and potential concerns involving immunogenicity, peptide-related impurities, and ingredient characterization.

Primary Research and Regulatory References

Posted on July 27, 2026August 28, 2026 by — Leave a comment

BPC-157 5mg Dosage Protocol

Preparation & Measurement Guide

BPC-157 5mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a BPC-157 5mg vial.

Research use only
Educational summary of a commonly documented convention. Not approved for human use.

Vial Size
BPC-157 5mg

Preparation
1mL bacteriostatic water

Concentration
5mg/mL after preparation

Documented Convention
200-600mcg once daily

1. Preparation and Measurement

BPC-157 5mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 5mg/mL. On a U-100 syringe, each unit contains 50mcg.

5mg / 1mL = 5mg/mL

1 U-100 unit = 0.01mL = 50mcg

Preparation

Draw 1mL of bacteriostatic water using sterile equipment.
Let the liquid run slowly down the inside wall of the vial.
Gently swirl until dissolved. Do not shake.
Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated research protocols. Frequency: once daily.

Period	Documented amount	Measurement
Weeks 1-2	200mcg once daily	0.04mL / 4 units
Weeks 3-4	400mcg once daily	0.08mL / 8 units
Weeks 5-8+	600mcg once daily	0.12mL / 12 units

Vial estimate: One 5mg vial contains approximately 25 administrations at the first listed amount or 8 at the final listed amount.

Practical Notes

The table applies only to this vial prepared with exactly 1mL.
Some entries are very small measurements; account for the accuracy of the measuring device.
Record the amount, date, and preparation used.

3. Supplies Needed

BPC-157 5mg vial.
1mL of bacteriostatic water per vial.
Sterile U-100 syringes.
Alcohol swabs.
Sharps container.

4. Storage and Handling

Keep unopened vials cool, dry, dark, and protected from moisture.
After preparation, refrigerate at 2-8 degrees C.
Protect from light and avoid repeated freeze-thaw cycles.
Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

BPC-157 has been examined mainly in animal and cell studies involving tendon response, fibroblasts, angiogenic signalling, wound models, and gastrointestinal injury. These findings do not establish human efficacy or a clinically validated dose.

BPC-157 is not an approved therapeutic drug. FDA materials note limited human safety information and concerns involving immunogenicity, peptide-related impurities, and ingredient characterization.